The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 12, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 12.
Number 5: On the same day that the President released his budget proposal that called for $2 billion less in funding for the National Institutes of Health than allocated by Congress, a new paper argued that a reduction in funding would significantly delay the emergence of new drugs.
Number 4: Roche has released phase 2 data for a novel drug that could compete with biosimilars of anti-vascular endothelial growth factor therapies.
Number 3: The White House’s Council of Economic Advisors said in a new white paper that the FDA should finalize biosimilar interchangeability guidelines that are easy and inexpensive to adhere to in order to promote competition.
Number 2: South Dakota became the latest state to pass legislation governing the substitution of interchangeable biosimilars for their reference products.
Number 1: Celltrion has received authorization to market its biosimilar trastuzumab, Herzuma, in the European Union.
Also this week, attorneys George Yu and Christopher Bruno, both of Schiff Hardin, explained how the Supreme Court’s eventual decision in the ongoing Oil States case could affect the biologics industry.
Finally, last week, our e-newsletter asked whether the United States should follow Australia’s lead by not using 4-letter suffixes in the names of biosimilars and biologics.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.